

Hemoglobinopathy Treatment Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/HA344247600BEN.html>

Date: March 2022

Pages: 60

Price: US\$ 3,250.00 (Single User License)

ID: HA344247600BEN

Abstracts

Hemoglobinopathy includes a range of disorders, which occur due to altered structure of hemoglobin.

This report contains market size and forecasts of Hemoglobinopathy Treatment in Global, including the following market information:

Global Hemoglobinopathy Treatment Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Hemoglobinopathy Treatment market was valued at 282.5 million in 2021 and is projected to reach US\$ 379.4 million by 2028, at a CAGR of 4.3% during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

Hydroxyurea Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Hemoglobinopathy Treatment include Novartis, AstraZeneca, Bluebird, Bristol-Myers Squibb, Emmaus Medical, Acceleron Pharma, HemaQuest Pharmaceuticals, Eli Lilly and Company and Celgene. etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Hemoglobinopathy

Treatment companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Hemoglobinopathy Treatment Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Hemoglobinopathy Treatment Market Segment Percentages, by Type, 2021 (%)

Hydroxyurea

Glutamine

Zynteglo

Other

Global Hemoglobinopathy Treatment Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Hemoglobinopathy Treatment Market Segment Percentages, by Application, 2021 (%)

Sickle Cell Diseases

Thalassemia

Global Hemoglobinopathy Treatment Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Hemoglobinopathy Treatment Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Hemoglobinopathy Treatment revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Hemoglobinopathy Treatment revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Novartis

AstraZeneca

Bluebird

Bristol-Myers Squibb

Emmaus Medical

Acceleron Pharma

HemaQuest Pharmaceuticals

Eli Lilly and Company

Celgene

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Hemoglobinopathy Treatment Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Hemoglobinopathy Treatment Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL HEMOGLOBINOPATHY TREATMENT OVERALL MARKET SIZE

- 2.1 Global Hemoglobinopathy Treatment Market Size: 2021 VS 2028
- 2.2 Global Hemoglobinopathy Treatment Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Hemoglobinopathy Treatment Players in Global Market
- 3.2 Top Global Hemoglobinopathy Treatment Companies Ranked by Revenue
- 3.3 Global Hemoglobinopathy Treatment Revenue by Companies
- 3.4 Top 3 and Top 5 Hemoglobinopathy Treatment Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Hemoglobinopathy Treatment Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Hemoglobinopathy Treatment Players in Global Market
 - 3.6.1 List of Global Tier 1 Hemoglobinopathy Treatment Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Hemoglobinopathy Treatment Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Hemoglobinopathy Treatment Market Size Markets, 2021 & 2028

4.1.2 Hydroxyurea

4.1.3 Glutamine

4.1.4 Zynteglo

4.1.5 Other

4.2 By Type - Global Hemoglobinopathy Treatment Revenue & Forecasts

4.2.1 By Type - Global Hemoglobinopathy Treatment Revenue, 2017-2022

4.2.2 By Type - Global Hemoglobinopathy Treatment Revenue, 2023-2028

4.2.3 By Type - Global Hemoglobinopathy Treatment Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Hemoglobinopathy Treatment Market Size, 2021 & 2028

5.1.2 Sickle Cell Diseases

5.1.3 Thalassemia

5.2 By Application - Global Hemoglobinopathy Treatment Revenue & Forecasts

5.2.1 By Application - Global Hemoglobinopathy Treatment Revenue, 2017-2022

5.2.2 By Application - Global Hemoglobinopathy Treatment Revenue, 2023-2028

5.2.3 By Application - Global Hemoglobinopathy Treatment Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Hemoglobinopathy Treatment Market Size, 2021 & 2028

6.2 By Region - Global Hemoglobinopathy Treatment Revenue & Forecasts

6.2.1 By Region - Global Hemoglobinopathy Treatment Revenue, 2017-2022

6.2.2 By Region - Global Hemoglobinopathy Treatment Revenue, 2023-2028

6.2.3 By Region - Global Hemoglobinopathy Treatment Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Hemoglobinopathy Treatment Revenue, 2017-2028

6.3.2 US Hemoglobinopathy Treatment Market Size, 2017-2028

6.3.3 Canada Hemoglobinopathy Treatment Market Size, 2017-2028

6.3.4 Mexico Hemoglobinopathy Treatment Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Hemoglobinopathy Treatment Revenue, 2017-2028

6.4.2 Germany Hemoglobinopathy Treatment Market Size, 2017-2028

6.4.3 France Hemoglobinopathy Treatment Market Size, 2017-2028

6.4.4 U.K. Hemoglobinopathy Treatment Market Size, 2017-2028

6.4.5 Italy Hemoglobinopathy Treatment Market Size, 2017-2028

6.4.6 Russia Hemoglobinopathy Treatment Market Size, 2017-2028

6.4.7 Nordic Countries Hemoglobinopathy Treatment Market Size, 2017-2028

6.4.8 Benelux Hemoglobinopathy Treatment Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Hemoglobinopathy Treatment Revenue, 2017-2028

6.5.2 China Hemoglobinopathy Treatment Market Size, 2017-2028

6.5.3 Japan Hemoglobinopathy Treatment Market Size, 2017-2028

6.5.4 South Korea Hemoglobinopathy Treatment Market Size, 2017-2028

6.5.5 Southeast Asia Hemoglobinopathy Treatment Market Size, 2017-2028

6.5.6 India Hemoglobinopathy Treatment Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Hemoglobinopathy Treatment Revenue, 2017-2028

6.6.2 Brazil Hemoglobinopathy Treatment Market Size, 2017-2028

6.6.3 Argentina Hemoglobinopathy Treatment Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Hemoglobinopathy Treatment Revenue, 2017-2028

6.7.2 Turkey Hemoglobinopathy Treatment Market Size, 2017-2028

6.7.3 Israel Hemoglobinopathy Treatment Market Size, 2017-2028

6.7.4 Saudi Arabia Hemoglobinopathy Treatment Market Size, 2017-2028

6.7.5 UAE Hemoglobinopathy Treatment Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Novartis

7.1.1 Novartis Corporate Summary

7.1.2 Novartis Business Overview

7.1.3 Novartis Hemoglobinopathy Treatment Major Product Offerings

7.1.4 Novartis Hemoglobinopathy Treatment Revenue in Global Market (2017-2022)

7.1.5 Novartis Key News

7.2 AstraZeneca

7.2.1 AstraZeneca Corporate Summary

7.2.2 AstraZeneca Business Overview

- 7.2.3 AstraZeneca Hemoglobinopathy Treatment Major Product Offerings
- 7.2.4 AstraZeneca Hemoglobinopathy Treatment Revenue in Global Market (2017-2022)
- 7.2.5 AstraZeneca Key News
- 7.3 Bluebird
 - 7.3.1 Bluebird Corporate Summary
 - 7.3.2 Bluebird Business Overview
 - 7.3.3 Bluebird Hemoglobinopathy Treatment Major Product Offerings
 - 7.3.4 Bluebird Hemoglobinopathy Treatment Revenue in Global Market (2017-2022)
 - 7.3.5 Bluebird Key News
- 7.4 Bristol-Myers Squibb
 - 7.4.1 Bristol-Myers Squibb Corporate Summary
 - 7.4.2 Bristol-Myers Squibb Business Overview
 - 7.4.3 Bristol-Myers Squibb Hemoglobinopathy Treatment Major Product Offerings
 - 7.4.4 Bristol-Myers Squibb Hemoglobinopathy Treatment Revenue in Global Market (2017-2022)
 - 7.4.5 Bristol-Myers Squibb Key News
- 7.5 Emmaus Medical
 - 7.5.1 Emmaus Medical Corporate Summary
 - 7.5.2 Emmaus Medical Business Overview
 - 7.5.3 Emmaus Medical Hemoglobinopathy Treatment Major Product Offerings
 - 7.5.4 Emmaus Medical Hemoglobinopathy Treatment Revenue in Global Market (2017-2022)
 - 7.5.5 Emmaus Medical Key News
- 7.6 Acceleron Pharma
 - 7.6.1 Acceleron Pharma Corporate Summary
 - 7.6.2 Acceleron Pharma Business Overview
 - 7.6.3 Acceleron Pharma Hemoglobinopathy Treatment Major Product Offerings
 - 7.6.4 Acceleron Pharma Hemoglobinopathy Treatment Revenue in Global Market (2017-2022)
 - 7.6.5 Acceleron Pharma Key News
- 7.7 HemaQuest Pharmaceuticals
 - 7.7.1 HemaQuest Pharmaceuticals Corporate Summary
 - 7.7.2 HemaQuest Pharmaceuticals Business Overview
 - 7.7.3 HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Major Product Offerings
 - 7.7.4 HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Revenue in Global Market (2017-2022)
 - 7.7.5 HemaQuest Pharmaceuticals Key News

7.8 Eli Lilly and Company

7.8.1 Eli Lilly and Company Corporate Summary

7.8.2 Eli Lilly and Company Business Overview

7.8.3 Eli Lilly and Company Hemoglobinopathy Treatment Major Product Offerings

7.8.4 Eli Lilly and Company Hemoglobinopathy Treatment Revenue in Global Market (2017-2022)

7.8.5 Eli Lilly and Company Key News

7.9 Celgene

7.9.1 Celgene Corporate Summary

7.9.2 Celgene Business Overview

7.9.3 Celgene Hemoglobinopathy Treatment Major Product Offerings

7.9.4 Celgene Hemoglobinopathy Treatment Revenue in Global Market (2017-2022)

7.9.5 Celgene Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Hemoglobinopathy Treatment Market Opportunities & Trends in Global Market
- Table 2. Hemoglobinopathy Treatment Market Drivers in Global Market
- Table 3. Hemoglobinopathy Treatment Market Restraints in Global Market
- Table 4. Key Players of Hemoglobinopathy Treatment in Global Market
- Table 5. Top Hemoglobinopathy Treatment Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Hemoglobinopathy Treatment Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Hemoglobinopathy Treatment Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Hemoglobinopathy Treatment Product Type
- Table 9. List of Global Tier 1 Hemoglobinopathy Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Hemoglobinopathy Treatment Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Hemoglobinopathy Treatment Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - Hemoglobinopathy Treatment Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - Hemoglobinopathy Treatment Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - Hemoglobinopathy Treatment Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global Hemoglobinopathy Treatment Revenue (US\$, Mn), 2017-2022
- Table 19. By Region - Global Hemoglobinopathy Treatment Revenue (US\$, Mn), 2023-2028
- Table 20. By Country - North America Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2022

Table 21. By Country - North America Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2023-2028

Table 30. Novartis Corporate Summary

Table 31. Novartis Hemoglobinopathy Treatment Product Offerings

Table 32. Novartis Hemoglobinopathy Treatment Revenue (US\$, Mn), (2017-2022)

Table 33. AstraZeneca Corporate Summary

Table 34. AstraZeneca Hemoglobinopathy Treatment Product Offerings

Table 35. AstraZeneca Hemoglobinopathy Treatment Revenue (US\$, Mn), (2017-2022)

Table 36. Bluebird Corporate Summary

Table 37. Bluebird Hemoglobinopathy Treatment Product Offerings

Table 38. Bluebird Hemoglobinopathy Treatment Revenue (US\$, Mn), (2017-2022)

Table 39. Bristol-Myers Squibb Corporate Summary

Table 40. Bristol-Myers Squibb Hemoglobinopathy Treatment Product Offerings

Table 41. Bristol-Myers Squibb Hemoglobinopathy Treatment Revenue (US\$, Mn), (2017-2022)

Table 42. Emmaus Medical Corporate Summary

Table 43. Emmaus Medical Hemoglobinopathy Treatment Product Offerings

Table 44. Emmaus Medical Hemoglobinopathy Treatment Revenue (US\$, Mn), (2017-2022)

Table 45. Acceleron Pharma Corporate Summary

Table 46. Acceleron Pharma Hemoglobinopathy Treatment Product Offerings

Table 47. Acceleron Pharma Hemoglobinopathy Treatment Revenue (US\$, Mn), (2017-2022)

Table 48. HemaQuest Pharmaceuticals Corporate Summary

Table 49. HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Product Offerings

Table 50. HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Revenue (US\$, Mn), (2017-2022)

Table 51. Eli Lilly and Company Corporate Summary

Table 52. Eli Lilly and Company Hemoglobinopathy Treatment Product Offerings

Table 53. Eli Lilly and Company Hemoglobinopathy Treatment Revenue (US\$, Mn), (2017-2022)

Table 54. Celgene Corporate Summary

Table 55. Celgene Hemoglobinopathy Treatment Product Offerings

Table 56. Celgene Hemoglobinopathy Treatment Revenue (US\$, Mn), (2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Hemoglobinopathy Treatment Segment by Type in 2021
- Figure 2. Hemoglobinopathy Treatment Segment by Application in 2021
- Figure 3. Global Hemoglobinopathy Treatment Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Hemoglobinopathy Treatment Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Hemoglobinopathy Treatment Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Hemoglobinopathy Treatment Revenue in 2021
- Figure 8. By Type - Global Hemoglobinopathy Treatment Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Hemoglobinopathy Treatment Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Hemoglobinopathy Treatment Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Hemoglobinopathy Treatment Revenue Market Share, 2017-2028
- Figure 12. US Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Hemoglobinopathy Treatment Revenue Market Share, 2017-2028
- Figure 16. Germany Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 23. By Region - Asia Hemoglobinopathy Treatment Revenue Market Share, 2017-2028
- Figure 24. China Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 25. Japan Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 26. South Korea Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028
- Figure 27. Southeast Asia Hemoglobinopathy Treatment Revenue, (US\$, Mn),

2017-2028

Figure 28. India Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Hemoglobinopathy Treatment Revenue Market Share, 2017-2028

Figure 30. Brazil Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Hemoglobinopathy Treatment Revenue Market Share, 2017-2028

Figure 33. Turkey Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Hemoglobinopathy Treatment Revenue, (US\$, Mn), 2017-2028

Figure 37. Novartis Hemoglobinopathy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. AstraZeneca Hemoglobinopathy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. Bluebird Hemoglobinopathy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Bristol-Myers Squibb Hemoglobinopathy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Emmaus Medical Hemoglobinopathy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Acceleron Pharma Hemoglobinopathy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. HemaQuest Pharmaceuticals Hemoglobinopathy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 44. Eli Lilly and Company Hemoglobinopathy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 45. Celgene Hemoglobinopathy Treatment Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Hemoglobinopathy Treatment Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/HA344247600BEN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/HA344247600BEN.html>